PDCD1 and colorectal carcinoma: Therefore, finding a way to overcome the limitations of ICI therapies in patients with hypermutated CRC is a key issue in order to improve the response to anti-PD-1/PD-L1-based immunotherapy and increase the therapeutic effect.